Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

P300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [RNA-Seq]

ABSTRACT: p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [RNA-Seq]

PROVIDER: PRJNA608445 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11167735_1.fastq.gz	Fastqsanger.gz
	SRR11167735_2.fastq.gz	Fastqsanger.gz
	SRR11167736_1.fastq.gz	Fastqsanger.gz
	SRR11167736_2.fastq.gz	Fastqsanger.gz
	SRR11167737_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia

Project description:p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia

| PRJNA608640 | ENA

p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [DIP-seq]

Project description:p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [DIP-seq]

| PRJNA608641 | ENA

p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [ChIP-seq]

Project description:p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [ChIP-seq]

| PRJNA608643 | ENA

p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [ATAC-Seq]

Project description:p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [ATAC-Seq]

| PRJNA608642 | ENA

p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [ChIP-seq II]

Project description:p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [ChIP-seq II]

| PRJNA646481 | ENA

p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [RNA-Seq]

Project description:The p300 lysine acetyltransferase (KAT) can function as an oncogene or a tumor suppressor in hematologic malignancies. We have identified a tumor suppressor role for p300 in myelodysplastic syndrome (MDS) driven by Tet2 deficiency. Compared to Tet2-null hematopoietic stem and progenitor cells (HSPCs), HSPCs lacking both p300 and Tet2 (double knock out, DKO) displayed enhanced proliferation and impaired differentiation. Consequently, p300Δ/Δ Tet2-/- mice developed acute myeloid leukemia. p300 loss in Tet2-/- HSPCs induced a global epigenomic reprogramming that enhanced leukemogenicity at least in part by increasing expression of Myb, as knock-down of Myb specifically hindered the proliferation of the DKO HSPCs. We show that p300 KAT activity regulates the function of Tet2 null HSPCs, and that augmenting p300 function impairs their unlimited self-renewal. Such a strategy could prove useful in individuals with Tet2 deficient hematopoiesis or MDS.

2021-11-03 | GSE145819 | GEO